Abstract

SAFETY AND EFFICACY OF TOLVAPTAN IN PATIENTS WITH HYPONATREMIA-A REVIEW

Dilip.C*, Sufna.M.M , Danisha P, Molniya Baby, Sajitha.M.K, Linu Mohan.P, Shinu.C.

Abstract

Hyponatremia is the most common electrolyte disorder which increases the morbidity and mortality in hospitalized patients and its management is incompletely established in clinical practice due to diversity in underlying disease states and varying pathophysiology. Tolvaptan is the first orally active, specific V2 receptor antagonist to be approved by FDA for treatment of hypervolemic and euvolemic hyponatremia under brand name Samsca. As the part of the study, ‘evaluation of safety and efficacy of tolvaptan in patients with hyponatremia’ a review on tolvaptan in the treatment of hyponatremia was conducted. Tolvaptan has significant evidence that it improves serum sodium concentration by increasing the electrolyte-free water clearance, there by facilitating its application in the treatment of euvolemic and hypervolemic hyponatremia. The drug was found highly effective in the treatment of hyponatremia associated with cardiac failure and in syndrome of inappropriate anti-diuretic hormone. Tolvaptan also proved to maintain increased serum sodium concentration by prolonged therapy in patients with chronic hyponatremia at a modest safety margin.

Keywords: FDA, hyponatremia, electrolyte